Tag: autoimmune treatment market forecast

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Autoimmune Treatment Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for autoimmune treatment has experienced swift expansion in recent years. The expected growth is from $7.72 billion in 2024 to $8.63 billion in 2025, with a compound annual growth rate (CAGR) of 11.7%. Factors contributing to the historic growth include rising occurrence rates, advancements in immunology, research breakthroughs in genetics, heightened patient awareness and advocacy, and supportive regulatory measures.

The market size of autoimmune treatment is set to experience a significant surge in the coming years, anticipated to reach $14.54 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 13.9%. This projected growth in the upcoming years can be credited to the development of precision medicine, the rise of small molecule therapies, novel pathway targeting, advances in gene therapy, enlarged biopharmaceutical expenditures, along with an expanding biosimilar market. Future market trends are expected to encompass improvements in biologics and targeted therapies, therapies modulating the immune response, a heightened emphasis on treating rare autoimmune illnesses, the use of telemedicine and remote patient monitoring, initiatives and approvals from regulatory bodies, and the integration of digital health resources.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7863&type=smp

What Are the Core Growth Drivers Propelling the Autoimmune Treatment Market Forward?

Expected advancements in the autoimmune treatment market can be attributed to heightened investments in the research and development of drugs for autoimmune diseases. Businesses strive for innovation by engaging in research and development, which ultimately leads to the creation of new products and services. In the context of autoimmune disease treatment, research and development of drugs can lead to the production of immune suppressive drugs that are chemically defined, orally active, low molecular weight, and have a tolerable impact during long-term treatment. For example, US-based pharmaceutical company Eli Lilly and Company, boosted their R&D investments from $7 billion in 2021 to $7.19 billion in 2022, marking an increase in their R&D expenditure as a revenue percentage from 24.8% to 25.19%. Thus, it’s clear that the growth of the autoimmune treatment market is spurred by escalating research and development investments in drug discovery.

What Segment Types Define the Autoimmune Treatment Market Structure?

The autoimmune treatmentmarket covered in this report is segmented –

1) By Product: Consumables And Assay Kits; Instruments; Services

2) By Service Type: Consultation And Diagnosis; Therapy And monitoring; Drug development

3) By Disease: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Sjögren’s Syndrome; Thyroiditis; Scleroderma; Other Diseases

4) By Drug Class: Anti-Inflammatory; Anti-Hyperglycemic; NSAIDs; Interferons; Other Drug Class

Subsegments:

1) By Consumables And Assay Kits: ELISA Kits; Reagents And Antibodies; Sample Collection Kits

2) By Instruments: Diagnostic Equipment; Imaging Systems

3) By Services: Testing And Diagnostics Services; Consultation And Support Services; Data Analysis And Interpretation Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7863&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Autoimmune Treatment Market?

North America was the largest region in the autoimmune treatment market in 2024. The regions covered in the autoimmune treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theAutoimmune Treatment Industry Evolution?

Innovations in technology are emerging as a significant trend in the autoimmune treatment market. Leading firms in this market are working on next-level technologies to maintain their market stance. For example, UCB, a pharmaceutical company based in Belgium, was granted approval by the U.S. Food and Drug Administration (FDA) in June 2023 for RYSTIGGO (rozanolixizumab-noli) to treat generalized myasthenia gravis (gMG) in adult patients with positive results for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The approval, which received an expedited Priority Review, makes RYSTIGGO the only FDA-approved therapy targeting both anti-AChR and anti-MuSK positive gMG, covering the two most common subtypes of this condition, potentially enhancing the efficiency of providers, improving treatment effectiveness, and ultimately bettering patient care.

View the full report here:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

What Is the Definition of the Autoimmune Treatment Market?

Autoimmune treatment refers to the management and care of a patient for the purpose of combating an autoimmune disease or disorder. This is a type of condition in which one’s immune system starts attacking its own body cells. The autoimmune treatment is used to treat autoimmune diseases.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7863

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Autoimmune Treatment Market?

In recent times, the size of the autoimmune treatment market has considerably expanded. The market, valued at $7.72 billion in 2024, is projected to increase to $8.66 billion in 2025, representing a compound annual growth rate (CAGR) of 12.1%. The growth witnessed in the historical period is primarily due to factors such as the rising prevalence of autoimmune disorders, advances in immunology, insights from genetic research, enhanced patient awareness and advocacy, and supportive regulatory frameworks.

What Growth Rate Is Forecasted for the Autoimmune Treatment Market by 2029?

Predictions indicate a swift expansion for the autoimmune treatment market in the coming years. By 2029, the market is set to reach a valuation of $14.66 billion, with a compound annual growth rate (CAGR) of 14.1%. Factors contributing to the growth during the forecast period include the advancement of precision medicine, the development of small molecule therapies, novel pathway targeting, gene therapy breakthroughs, increased biopharmaceutical investments, and an expanding biosimilar market. Key trends set to define the era ahead include breakthroughs in targeted therapies and biologics, immunomodulatory treatments, emphasis on rare autoimmune diseases, the implementation of telemedicine and remote monitoring, regulatory measures and drug approvals, as well as the integration of digital health tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7863&type=smp

Which Key Companies Are Shaping the Future of the Autoimmune Treatment Market?

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Pfizer Inc., Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., Amarin Corporation PLC, AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., bluebird bio Inc., Cabaletta Bio Inc., Catabasis Pharmaceuticals Inc., ChemoCentryx Inc., Coherus BioSciences Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited, Cumberland Pharmaceuticals Inc., CytoDyn Inc.

Which Factors Are Driving Demand in the Autoimmune Treatment Industry?

The rise in funding for research and development of medications for autoimmune conditions is anticipated to fuel the growth of the autoimmune treatment market. Businesses carry out research and development to foster innovation and unveil new products or services. With regard to autoimmune diseases, research and drug development pave the way for the creation of more precise, low molecular weight, orally administered immune suppressive drugs that are chemically characterized and bear acceptable tolerability for long-term treatment. For instance, Eli Lilly and Company, a pharmaceutical firm based in the US, boosted its investment in R&D from $7 billion in 2021 to $7.19 billion in 2022. This led to an expansion in its R&D expenditure in terms of revenue percentage, from 24.8% to 25.19%. Hence, the escalation in investments in the research and development of drugs stimulates the growth of the autoimmune treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7863&type=smp

How Is the Autoimmune Treatment Market Segmented by Several Divisions?

The autoimmune treatment market covered in this report is segmented –

1) By Product: Consumables And Assay Kits, Instruments, Services

2) By Service Type: Consultation And Diagnosis, Therapy And monitoring, Drug development

3) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases

4) By Drug Class: Anti-Inflammatory, Anti-Hyperglycemic, NSAIDs, Interferons, Other Drug Class

Subsegments:

1) By Consumables And Assay Kits: ELISA Kits, Reagents And Antibodies, Sample Collection Kits

2) By Instruments: Diagnostic Equipment, Imaging Systems

3) By Services: Testing And Diagnostics Services, Consultation And Support Services, Data Analysis And Interpretation Services

What are the Emerging Market Trends Driving the Growth of the Autoimmune Treatment Industry?

There is a rising trend towards technological innovation within the autoimmune treatment market. The leading firms in this industry are utilizing ground-breaking technology to secure their market positions. For example, in June 2023, the U.S. Food and Drug Administration (FDA) endorsed RYSTIGGO (rozanolixizumab-noli), a medicine developed by the Belgium-based pharmaceutical company UCB, for the management of generalized myasthenia gravis (gMG) in adults testing positive for anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The approval was fast-tracked under Priority Review. Notably, RYSTIGGO is the solitary FDA-recognized treatment for both anti-AchR and anti-MuSK antibody-positive gMG, addressing the two most common forms of this condition. This in turn could bolster healthcare provider effectiveness, enhance the success of treatment plans, and improve overall patient health.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Which Regions Are Driving Growth in the Autoimmune Treatment Market?

North America was the largest region in the autoimmune treatment market in 2024. The regions covered in the autoimmune treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7863

This Report Delivers Insight On:

1. How big is the autoimmune treatment market, and how is it changing globally?

2. Who are the major companies in the autoimmune treatment market, and how are they performing?

3. What are the key opportunities and risks in the autoimmune treatment market right now?

4. Which products or customer segments are growing the most in the autoimmune treatment market?

5. What factors are helping or slowing down the growth of the autoimmune treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Autoimmune Treatment Market?

In recent times, the size of the autoimmune treatment market has considerably expanded. The market, valued at $7.72 billion in 2024, is projected to increase to $8.66 billion in 2025, representing a compound annual growth rate (CAGR) of 12.1%. The growth witnessed in the historical period is primarily due to factors such as the rising prevalence of autoimmune disorders, advances in immunology, insights from genetic research, enhanced patient awareness and advocacy, and supportive regulatory frameworks.

What Growth Rate Is Forecasted for the Autoimmune Treatment Market by 2029?

Predictions indicate a swift expansion for the autoimmune treatment market in the coming years. By 2029, the market is set to reach a valuation of $14.66 billion, with a compound annual growth rate (CAGR) of 14.1%. Factors contributing to the growth during the forecast period include the advancement of precision medicine, the development of small molecule therapies, novel pathway targeting, gene therapy breakthroughs, increased biopharmaceutical investments, and an expanding biosimilar market. Key trends set to define the era ahead include breakthroughs in targeted therapies and biologics, immunomodulatory treatments, emphasis on rare autoimmune diseases, the implementation of telemedicine and remote monitoring, regulatory measures and drug approvals, as well as the integration of digital health tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7863&type=smp

Which Key Companies Are Shaping the Future of the Autoimmune Treatment Market?

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Pfizer Inc., Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., Amarin Corporation PLC, AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., bluebird bio Inc., Cabaletta Bio Inc., Catabasis Pharmaceuticals Inc., ChemoCentryx Inc., Coherus BioSciences Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited, Cumberland Pharmaceuticals Inc., CytoDyn Inc.

Which Factors Are Driving Demand in the Autoimmune Treatment Industry?

The rise in funding for research and development of medications for autoimmune conditions is anticipated to fuel the growth of the autoimmune treatment market. Businesses carry out research and development to foster innovation and unveil new products or services. With regard to autoimmune diseases, research and drug development pave the way for the creation of more precise, low molecular weight, orally administered immune suppressive drugs that are chemically characterized and bear acceptable tolerability for long-term treatment. For instance, Eli Lilly and Company, a pharmaceutical firm based in the US, boosted its investment in R&D from $7 billion in 2021 to $7.19 billion in 2022. This led to an expansion in its R&D expenditure in terms of revenue percentage, from 24.8% to 25.19%. Hence, the escalation in investments in the research and development of drugs stimulates the growth of the autoimmune treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7863&type=smp

How Is the Autoimmune Treatment Market Segmented by Several Divisions?

The autoimmune treatment market covered in this report is segmented –

1) By Product: Consumables And Assay Kits, Instruments, Services

2) By Service Type: Consultation And Diagnosis, Therapy And monitoring, Drug development

3) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases

4) By Drug Class: Anti-Inflammatory, Anti-Hyperglycemic, NSAIDs, Interferons, Other Drug Class

Subsegments:

1) By Consumables And Assay Kits: ELISA Kits, Reagents And Antibodies, Sample Collection Kits

2) By Instruments: Diagnostic Equipment, Imaging Systems

3) By Services: Testing And Diagnostics Services, Consultation And Support Services, Data Analysis And Interpretation Services

What are the Emerging Market Trends Driving the Growth of the Autoimmune Treatment Industry?

There is a rising trend towards technological innovation within the autoimmune treatment market. The leading firms in this industry are utilizing ground-breaking technology to secure their market positions. For example, in June 2023, the U.S. Food and Drug Administration (FDA) endorsed RYSTIGGO (rozanolixizumab-noli), a medicine developed by the Belgium-based pharmaceutical company UCB, for the management of generalized myasthenia gravis (gMG) in adults testing positive for anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The approval was fast-tracked under Priority Review. Notably, RYSTIGGO is the solitary FDA-recognized treatment for both anti-AchR and anti-MuSK antibody-positive gMG, addressing the two most common forms of this condition. This in turn could bolster healthcare provider effectiveness, enhance the success of treatment plans, and improve overall patient health.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

Which Regions Are Driving Growth in the Autoimmune Treatment Market?

North America was the largest region in the autoimmune treatment market in 2024. The regions covered in the autoimmune treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7863

This Report Delivers Insight On:

1. How big is the autoimmune treatment market, and how is it changing globally?

2. Who are the major companies in the autoimmune treatment market, and how are they performing?

3. What are the key opportunities and risks in the autoimmune treatment market right now?

4. Which products or customer segments are growing the most in the autoimmune treatment market?

5. What factors are helping or slowing down the growth of the autoimmune treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Factors Are Propelling the Market Growth of theAutoimmune Treatment Market from 2025 to 2034?

The growth of the autoimmune treatment market is predicted to be fueled by the rise in investments for researching and developing autoimmune disease drugs. Businesses progress via research and development, which aids in innovating and introducing new products or services. By focusing on research and development for autoimmune disease drugs, more efficacious, low-molecular-weight, orally active and chemically defined immune suppressants are created that offer satisfactory tolerability for sustained autoimmune disease management. For example, Eli Lilly and Company, a pharmaceutical corporation based in the United States, heightened its research and development investment from $7 billion in 2021 to $7.19 billion in 2022. This resulted in an escalation of its research and development outlay from 24.8% to 25.19% of revenue. Hence, this surge in investments for researching and developing drugs propels the expansion of the autoimmune treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7863&type=smp

#How Will the CAGR of the Autoimmune Treatment Market Influence Its Overall Growth by 2034?

The market for autoimmune treatments has seen significant growth recently. Its size is projected to expand from $7.72 billion in 2024 to $8.66 billion in 2025, suggesting a compound annual growth rate (CAGR) of 12.1%. Factors that have contributed to this increased growth during the previous period include the rising prevalence of autoimmune diseases, progress in immunology, insights from genetic research, heightened patient awareness and advocacy, as well as regulatory support.

Expectations are high for a substantial expansion in the autoimmune treatment market size over the coming years. Forecasts predict growth to $14.66 billion by 2029, with a compound annual growth rate (CAGR) of 14.1%. Factors contributing to this expected rise during the forecasting period include the precision medicine methodologies, growth of small molecule therapies, new pathway targeting, groundbreaking gene therapy, increased biopharmaceutical investments, and the upswing in the biosimilar market. Other significant trends include progression in biologics and targeted treatments, the use of immunomodulatory therapies, attention to rare autoimmune disorders, deployment of telemedicine and remote monitoring, regulatory moves and drug green lights, as well as the incorporation of digital health instruments.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7863

How Are Market Trends and Innovations Revolutionizing theAutoimmune Treatment Industry in Recent Times?

The rising popularity of technological innovations is an important trend in the autoimmune treatment market. To maintain their market position, major companies are progressing with cutting-edge technologies. For instance, the US Food and Drug Administration (FDA) approved RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients positive for either anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies in June 2023. This approval, given to the Belgium-based pharmaceutical firm UCB under Priority Review, positions RYSTIGGO as the sole FDA-approved therapy for both anti-AchR and anti-MuSK antibody-positive gMG, covering the two most common subtypes of this autoimmune disease. This could enhance the efficiency of healthcare providers, improve the effectiveness of treatment methods, and provide better patient care.

Which Key Market Players Are Shaping the Future and Growth of theAutoimmune Treatment Market?

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Pfizer Inc., Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., Amarin Corporation PLC, AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., bluebird bio Inc., Cabaletta Bio Inc., Catabasis Pharmaceuticals Inc., ChemoCentryx Inc., Coherus BioSciences Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited, Cumberland Pharmaceuticals Inc., CytoDyn Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

What Are the Core Segments of the Autoimmune Treatment Market, and How Do They Contribute to Growth?

The autoimmune treatment market covered in this report is segmented –

1) By Product: Consumables And Assay Kits, Instruments, Services

2) By Service Type: Consultation And Diagnosis, Therapy And monitoring, Drug development

3) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases

4) By Drug Class: Anti-Inflammatory, Anti-Hyperglycemic, NSAIDs, Interferons, Other Drug Class

Subsegments:

1) By Consumables And Assay Kits: ELISA Kits, Reagents And Antibodies, Sample Collection Kits

2) By Instruments: Diagnostic Equipment, Imaging Systems

3) By Services: Testing And Diagnostics Services, Consultation And Support Services, Data Analysis And Interpretation Services

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=7863&type=smpGlobal Autoimmune Treatment Market, Global Autoimmune Treatment Market Report, Global Autoimmune Treatment Market Trends, Global Autoimmune Treatment Market Size

Browse Through More Reports Similar to the Gobal Autoimmune Treatment Maret 2025, By The Business Research Company:

Macular Degeneration Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Neutropenia Biologic Drug Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the autoimmune treatment market grown over the years?

In recent times, the market size for autoimmune treatment has seen a significant surge. Expected to expand from $7.72 billion in 2024 to $8.66 billion in 2025, the compound annual growth rate (CAGR) stands at 12.1%. Factors such as the rising incidence, developments in the field of immunology, insights from genetic research, patient awareness and advocacy, as well as regulatory support, have contributed to the growth witnessed during the previous period.

What Is the forecasted market size and growth rate for the autoimmune treatment market?

Anticipated to experience swift expansion in the upcoming years, the autoimmune treatment market is predicted to surge to a value of $14.66 billion in 2029, with a compound annual growth rate (CAGR) of 14.1%. This projected surge in the forecast period is largely due to advancements in precision medicine, breakthroughs in small molecule therapies, novel pathway targeting, developments in gene therapy, increased biopharmaceutical investments, and growth in the biosimilar market. The onward outlook also highlights key trends such as progress in biologic and targeted therapies, immunomodulatory treatments, focus on rare autoimmune disorders, the application of telemedicine and remote monitoring, regulatory initiatives and drug sanctions, and the incorporation of digital health tools.

Get your autoimmune treatment market report here!

https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report

What are the major factors driving growth in the autoimmune treatment market?

The escalation in financial outlays towards scientific investigation and creation of treatments for autoimmune diseases is anticipated to spur the expansion of the autoimmune treatment market. Research and development essentially represent the measures taken by businesses to innovate and introduce novel products and services. They enable the design and introduction of more precise, low-molecular-weight, orally administered, and chemically outlined suppressive medicines for the immune system that exhibit acceptable tolerability in the long-term treatment of autoimmune disease. For example, in January 2022, Eli Lilly and Company, a pharmaceutical outfit based in the United States, amplified its monetary commitment towards research and development from $7 billion in 2021 to $7.19 billion in 2022. This resulted in growth of its research and development expenditures as a relative proportion of revenue from 24.8% to 25.19%. Thus, the escalating financial contributions towards research and development of medications fuels the upward trajectory of the autoimmune treatment market.

What key areas define the segmentation of the global autoimmune treatment Market?

The autoimmune treatment market covered in this report is segmented –

1) By Product: Consumables And Assay Kits, Instruments, Services

2) By Service Type: Consultation And Diagnosis, Therapy And monitoring, Drug development

3) By Disease: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases

4) By Drug Class: Anti-Inflammatory, Anti-Hyperglycemic, NSAIDs, Interferons, Other Drug Class

Subsegments:

1) By Consumables And Assay Kits: ELISA Kits, Reagents And Antibodies, Sample Collection Kits

2) By Instruments: Diagnostic Equipment, Imaging Systems

3) By Services: Testing And Diagnostics Services, Consultation And Support Services, Data Analysis And Interpretation Services

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7863&type=smp

What are the top market players propelling the growth of the autoimmune treatment industry?

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Johnson & Johnson Services Inc., Eli Lilly and Company, Pfizer Inc., Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Autoimmune Inc., Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., Biogen Idec Inc., Bayer Schering Pharma AG, GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., Amarin Corporation PLC, AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Biohaven Pharmaceutical Holding Company Ltd., BioMarin Pharmaceutical Inc., bluebird bio Inc., Cabaletta Bio Inc., Catabasis Pharmaceuticals Inc., ChemoCentryx Inc., Coherus BioSciences Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited, Cumberland Pharmaceuticals Inc., CytoDyn Inc.

What are the key trends shaping the future of the autoimmune treatment market?

The rise in technological advances is a key factor driving trends in the autoimmune treatment market. Top companies present in this market are crafting cutting-edge technology to maintain their dominance. For example, UCB, a pharmaceutical organization based in Belgium, gained approval from the U.S. Food and Drug Administration (FDA) for its RYSTIGGO (rozanolixizumab-noli) in June 2023. This was for treating generalised myasthenia gravis (gMG) in adults who tested positive for either anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. This approval process was fast-tracked under Priority Review and RYSTIGGO presents itself as the only FDA-approved therapy for both anti-AchR and anti-MuSK antibody-positive gMG. This covers the two most common subcategories of this condition. These autoimmune disease diagnoses can potentially enhance healthcare provider productivity, boost the success of treatments, and better patient care.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7863

What regions are dominating the autoimmune treatment market growth?

North America was the largest region in the autoimmune treatment market in 2024. The regions covered in the autoimmune treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Macular Degeneration Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/macular-degeneration-treatment-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Neutropenia Biologic Drug Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: